Clear Cell Renal Cell Carcinoma malady

NIH Rare Diseases: Clear cell renal cell carcinoma is a cancer of the kidney.  The name "clear cell" refers to the appearance of the cancer cells when viewed with a microscope.  Clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (mass).  Though the exact cause of clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several genetic predisposition conditions (such as von Hippel Lindau syndrome) may contribute to the development of this type of cancer.  Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy.³⁰

MalaCards: Clear Cell Renal Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma (subtype), is related to renal cell carcinoma and hemangioblastoma. An important gene associated with Clear Cell Renal Cell Carcinoma is CA9 (carbonic anhydrase IX), and among its related pathways are Transcription P53 signaling pathway and Renal cell carcinoma. The compounds glucose and threonine have been mentioned in the context of this disorder. Affiliated tissues include brain, kidney and thyroid, and related mouse phenotypes are respiratory system and endocrine/exocrine gland.

clear cell renal cell carcinoma 30 clear-cell metastatic renal cell carcinoma (subtype) 30 conventional (clear cell) renal cell carcinoma 43

cystic-multilocular variant 30 clear cell rcc 30

Diseases related to clear cell renal cell carcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 672)

id	Related Disease	Score	Top Affiliating Genes
1	renal cell carcinoma	33.6	RELA, KIT, SFRP1, SETD2, VIM, VHL
2	hemangioblastoma	31.6	VIM, VHL, VEGFA, KDR, MUC1, MME
3	collecting duct carcinoma	30.2	VIM, VHL, PBRM1, MUC1, CDKN1B, FLCN
4	chromophobe renal cell carcinoma	29.2	KIT, VIM, VHL, PBRM1, MUC1, MME
5	germ cell tumor	27.5	KIT, VHL, VEGFA, RASSF1, BIRC5, CGB
6	renal clear cell carcinoma	26.7	SETD2, VIM, VHL, VEGFA, RASSF1, BIRC5
7	carcinoma	25.8	LRRC2, RELA, KIT, SFRP1, BTG2, SETD2
8	hypoxia	22.3	RELA, KIT, SFRP1, SETD2, SERPINF1, SERPINE1
9	thyroiditis	17.9	RELA, KIT, SETD2, SERPINE1, VIM, VHL
10	hepatitis	17.3	RELA, KIT, SFRP1, SETD2, SERPINF1, SERPINE1
11	prostatitis	16.0	RELA, KIT, SFRP1, BTG2, SETD2, SEMA3B
12	endolymphatic sac tumor	13.9	SETD2, VHL, CA9, HIF1A, EPO, EPOR
13	adenofibroma	13.9	MME, INHA, CALB2, PTEN
14	inverted papilloma	13.8	FSCN1, CDKN1B, MKI67, IFI27
15	horseshoe kidney	13.8	MME, CALB2, CA9, KRT7, EPO
16	lymphedema, congenital	13.8	VEGFC, FLT4, FIGF
17	nephrogenic adenoma	13.8	PAX8, PAX2, MUC1, KRT7
18	mixed epithelial stromal tumour	13.8	MME, INHA, CALB2
19	polycystic kidney disease	13.7	VHL, PAX2, MTOR, HGF, EPO
20	dysgerminoma	13.7	KIT, CGB, INHA, PTEN, RNF139, WT1
21	erythrocytosis	13.7	SETD2, VHL, IGFBP3, HIF1A, EPAS1, EPO
22	monophasic synovial sarcoma	13.7	RASSF1, MUC1, CALB2
23	capillary hemangioma	13.7	VEGFA, KDR, FLT4, SLC2A1
24	acute mountain sickness	13.7	VHL, VEGFA, FLT1, HIF1A
25	primary polycythemia	13.6	EPAS1, EPO, EPOR
26	breast fibroadenoma	13.6	VEGFC, RASSF1, MME, MKI67, ETS1, TIMP2
27	invasive bladder transitional cell carcinoma	13.6	CDKN1A, IFI27, EGFR
28	serous cystadenocarcinoma	13.6	MMP2, TYMP, DPP4
29	pneumothorax	13.6	KDR, MUC1, FNIP1, FLCN, CALB2
30	alveolar rhabdomyosarcoma	13.6	CDK4, FOXO1, MDM2, IGF1R, DIABLO, WT1
31	diffuse astrocytoma	13.6	CDK4, MKI67, TNC, PTEN, EGFR, TIMP3
32	adenosarcoma	13.6	KIT, MME, MKI67, CALB2, WT1
33	reticulosarcoma	13.6	MUC1, FSCN1, CDKN1B, ANPEP, DPP4, CXCR3
34	doxorubicin induced cardiomyopathy	13.6	MET, EGFR, HGF, EPOR
35	large cell carcinoma	13.5	CDK2, CDK4, KRT7, KRT5, EGFR, TIMP2
36	posterior uveal melanoma	13.5	VEGFA, BIRC5, MMP9, MKI67
37	neuroendocrine tumor	13.5	RAF1, RASSF1, PAX8, MTOR, MKI67, IGF1R
38	bile duct cancer	13.5	VEGFA, FSCN1, CDKN1A, TYMP
39	myeloproliferative disorder	13.5	KIT, RAN, KDR, ANPEP, PDGFRB, EPO
40	thrombocytosis	13.5	VEGFA, CALB2, PDGFRB, TYMP, EPO, EPOR
41	nodular malignant melanoma	13.5	VEGFA, MYC, CDKN1A, HIF1A, TYMP, EPAS1
42	hemangioendothelioma	13.5	VHL, VEGFA, KDR, FLT1, FLT4, MDM2
43	ovarian cancer	13.4	CDKN1A, CDK2, CDKN1B, CDK4, CCNE1, E2F1
44	septic arthritis	13.4	RELA, MMP2, MMP9, TLR3, CXCR3
45	sex cord-gonadal stromal tumor	13.4	VIM, INHA, CALB2
46	male germ cell tumor	13.4	KIT, RASSF1, CDKN1A, CDK2, MDM2, APAF1
47	pulmonary hypertension	13.4	SETD2, FLT1, CAV1, TNC, RHOA, RHOD
48	nasopharynx carcinoma	13.4	VEGFA, RASSF1, CDH1, MMP9, EGFR
49	basaloid squamous cell carcinoma	13.4	MYC, BIRC5, CDKN1B, CDH1, MKI67
50	corneal neovascularization	13.4	SERPINF1, VEGFA, KDR, MMP2, FLT1, TIMP2

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to clear cell renal cell carcinoma:

²²

MGI Mouse Phenotypes related to clear cell renal cell carcinoma:

²⁵ (show all 27)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.1	EPAS1, ROBO1, THRB, DACH1, GREM1, SCNN1B
2	endocrine/exocrine gland phenotype	MP:0005379	10.0	APAF1, AQP1, INHA, CDKN1B, PAX2, PAX8
3	craniofacial phenotype	MP:0005382	9.4	PDGFRB, KIT, PAX8, T, FOXO1, IGF1R
4	liver/biliary system phenotype	MP:0005370	9.0	EPO, EPAS1, HIF1A, EGFR, MET, VEGFA
5	normal phenotype	MP:0002873	8.7	GRPR, EPOR, EPO, FIGF, FLT4, FLT1
6	hematopoietic system phenotype	MP:0005397	8.3	FHIT, INHA, CDK4, CD74, CDKN1A, CD276
7	limbs/digits/tail phenotype	MP:0005371	8.1	MET, MMP9, T, VEGFA, VHL, SFRP1
8	hearing/vestibular/ear phenotype	MP:0005377	8.1	CALB1, TNC, PPARG, NFKB1, EGFR, THRB
9	reproductive system phenotype	MP:0005389	7.7	ANPEP, APAF1, GREM1, INHA, FLT1, MMP9
10	no phenotypic analysis	MP:0003012	7.6	MUC1, T, PPARG, MYC, VEGFA, SEMA5B
11	integument phenotype	MP:0010771	6.6	E2F1, NPEPPS, TFAP2A, TGFA, EGFR, KRT5
12	adipose tissue phenotype	MP:0005375	6.6	E2F1, PRKCE, TCF7L2, TGFBR2, TGFB1, TGFA
13	behavior/neurological phenotype	MP:0005386	6.5	EIF2AK3, LSAMP, KRT5, NFKB1, PPARG, SPP1
14	skeleton phenotype	MP:0005390	6.0	SFRP1, KIT, RELA, BTG2, EPAS1, E2F1
15	nervous system phenotype	MP:0003631	5.9	DACH1, PTEN, TERT, TNC, CAV1, CASP8
16	vision/eye phenotype	MP:0005391	5.0	MMP9, RELA, KIT, SERPINF1, MMP2, CDK4
17	muscle phenotype	MP:0005369	3.7	TIMP3, TLR3, HIF1A, EGFR, WT1, PDGFRB
18	tumorigenesis	MP:0002006	INF	E2F1, ROBO1, CXCR3, PSCA, TCF7L2, TGFBR2
19	digestive/alimentary phenotype	MP:0005381	INF	F2R, IGF1R, ANGPTL4, APAF1, MDM2, MET
20	homeostasis/metabolism phenotype	MP:0005376	INF	RELA, KIT, GNAS, MET, FHIT, INHA
21	mortality/aging	MP:0010768	INF	FADD, CIAPIN1, SCNN1B, KDR, PAX2, PAX8
22	growth/size phenotype	MP:0005378	INF	NPEPPS, PRKCE, DPP4, TGFBR2, TGFBI, TGFA
23	immune system phenotype	MP:0005387	INF	EPOR, EPAS1, E2F1, NPEPPS, PRKCE, TFAP2A
24	renal/urinary system phenotype	MP:0005367	INF	PDGFRB, PAX8, RASSF5, VHL, KIT, PAX2
25	cardiovascular system phenotype	MP:0005385	INF	FOXO1, RAF1, MYC, VEGFC, VEGFA, VHL
26	cellular phenotype	MP:0005384	INF	EPOR, EPO, EPCAM, HGF, E2F1, ROBO1
27	embryogenesis phenotype	MP:0005380	INF	MET, SETD2, SFRP1, KIT, VIM, BRK1

Articles related to clear cell renal cell carcinoma:

(show top 50)    (show all 140)

id	Title	Authors	Year	Affiliating Genes
1	PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangi oblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. (21263247)	Carney E.M.... Netto G.J.	2011	PAX2, INHA, PAX8
2	Mutations of the von Hippel-Lindau gene confer increa sed susceptibility to natural killer cells of clear-cell renal cell carcinoma. (21258414)	Perier A.... Caignard A.	2011	VHL
3	HtrA3 is regulated by 15-deoxy-Delta12,14-prostagland in J2 independently of PPARgamma in clear cell renal cell carcinomas. (19951697)	ThAcoleyre S.... Denis M.G.	2010	PPARG, GTF3A, HTRA3
4	Wilms' tumour 1 can suppress hTERT gene expression an d telomerase activity in clear cell renal cell carcinoma via multiple pathways. (20842112)	Sitaram R.T.... Li A.	2010	TERT, WT1
5	Tumor-associated macrophages in clear cell renal cell carcinoma express both gastrin-releasing peptide and its receptor: a possible modulatory role of immune effectors cells. (20012906)	Bedke J.... Heuser M.	2010	GRPR
6	Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. (20454689)	Verine J.... Germain S.	2010	VHL, ANGPTL4
7	Loss of expression of TIMP3 in clear cell renal cell carcinoma. (20194016)	Masson D.... Denis M.G.	2010	KDR, VEGFA, TIMP3
8	Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. (20042676)	van Vlodrop I.J.... van Engeland M.	2010	GREM1
9	Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. (20420713)	Liu H.... Bhanot G.V.	2010	LOX, LRRC2
10	Expression of COX-2 and VEGF and their correlation w ith angiogenesis in human clear cell renal cell carcinoma (20021866)	Chang B.D.... Zhou H.L.	2009	VEGFA, PTGS2
11	MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. (18809243)	Tang S.W.... Lin J.Y.	2009	PGK1, MYC
12	VHL loss of function and its impact on oncogenic sign aling networks in clear cell renal cell carcinoma. (18950731)	Linehan W.M.... Bottaro D.P.	2009	VHL
13	Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. (19731255)	Kats-Ugurlu G.... Leenders W.	2009	VEGFA
14	Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. (19401348)	Luu V.D.... Moch H.	2009	VHL, PAX2, EPAS1
15	Expression of aquaporin 1 in primary renal tumors: a prognostic indicator for clear-cell renal cell carcinoma. (18930582)	Huang Y.... Yao M.	2009	AQP1
16	High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma. (18241036)	Abe H.... Yoshida K.	2008	RAN
17	Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. (18319552)	Tanimoto S.... Kanayama H.O.	2008	HGF
18	The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker. (18685487)	Gokden N.... McKenney J.K.	2008	PAX2, MOK
19	Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. (18464292)	Patard J.J.... Pantuck A.J.	2008	CA9, VHL
20	Sporadic clear cell renal cell carcinoma with diffuse cytokeratin 7 immunoreactivity. (18604734)	Mai K.T.... Wang D.	2008	KRT7
21	Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. (18694993)	Crispen P.L.... Kwon E.D.	2008	CD276
22	Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. (18614849)	Abe H.... Yoshida K.	2008	RHOA, RHOC, RHOB
23	Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component. (18669473)	Skapa P.... Zamecnik J.	2008	CA9
24	DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma. (17443497)	Al-Sarraf N.... Gray S.G.	2007	DOK4
25	High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. (17505508)	Baldewijns M.M.... Vermeulen P.B.	2007	CA9
26	Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. (17616938)	Faronato M.... Procopio A.	2007	VHL, ALOX5
27	Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. (17699851)	Gumz M.L.... Copland J.A.	2007	SFRP1
28	Elevated cyclin E level in human clear cell renal cell carcinoma: possible causes and consequences. (17726548)	Nauman A.... Puzianowska-Kuznicka M.	2007	CCNE1, E2F1
29	Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. (17311301)	Cascon A.... Robledo M.	2007	VHL, BRK1
30	mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype. (17945286)	Christoph F.... Miller K.	2007	APAF1
31	The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. (17553206)	Cohen D.... Zhou M.	2007	EGFR
32	Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. (17572184)	Kawata N.... Takahashi S.	2007	MMP2, MMP9, TIMP2
33	Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. (18094421)	Klatte T.... Belldegrun A.S.	2007	VEGFA, HIF1A, CA9
34	Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. (17594714)	Tollefson M.K.... Kwon E.D.	2007	MKI67
35	Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. (16985214)	Varona A.... Larrinaga G.	2007	ANPEP, ENPEP, NPEPPS
36	Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. (17906660)	Gervais M.L.... Ohh M.	2007	CDH1, VHL
37	Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. (17034508)	Lee S.E.... Hong S.K.	2006	SLPI
38	Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma. (16964377)	Hirota E.... Katagiri T.	2006	SEMA5B
39	Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma. (16627979)	Gong K.... Na Y.	2006	EPOR, EPO
40	Expression of cytokeratin 5 and calretinin in clear-cell renal cell carcinoma (16838608)	Cid Mouteira P.... Anton Badiola I.	2006	KRT5, CALB2
41	The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. (16467086)	Frey U.H.... Eisenhardt A.	2006	GNAS
42	Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. (16425993)	Gollob J.A.	2005	RAF1, KDR, PDGFRB
43	mRNA expression analysis of metastatic markers in clear-cell renal cell carcinoma (18035688)	Struckmann K.... Moch H.	2005	MMP2, MMP9, TIMP2
44	Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma. (15893810)	Parker A.S.... Blute M.L.	2005	VHL
45	Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. (15086915)	Vila M.R.... Meseguer A.	2004	DPP4, F2R, HAVCR1
46	Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. (14764125)	Joo H.J.... Kim S.J.	2004	CAV1
47	Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. (12853790)	Parker A.... Blute M.L.	2003	IGF1R
48	Specific von Hippel-Lindau protein expression of clear cell renal cell carcinoma with 'immunogenic' features. (11349220)	Magyarlaki T.... Nagy J.	2001	VHL
49	Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. (10807693)	Woodward E.R.... Maher E.R.	2000	MET
50	VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. (10766184)	Brauch H.... Decker H.J.	2000	VHL

Genes related to clear cell renal cell carcinoma according to GeneCards:

(show top 50)    (show all 147)

id	Symbol	Description	Score	GeneCards Section Context
1	CA9	carbonic anhydrase IX	11.1	Publications, Summaries
2	PBRM1	polybromo 1	11.0	Summaries
3	MIR9-3	microRNA 9-3	11.0	Publications
4	MIR9-1	microRNA 9-1	11.0	Publications
5	MT1G	metallothionein 1G	11.0	Publications
6	VHL	von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase	11.0	Publications
7	SEMA3B	sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B	11.0	Publications
8	ESM1	endothelial cell-specific molecule 1	11.0	Publications
9	DNPEP	aspartyl aminopeptidase	11.0	Publications
10	DOK4	docking protein 4	11.0	Publications
11	DUSP9	dual specificity phosphatase 9	11.0	Publications
12	RNF139	ring finger protein 139	11.0	Publications
13	BRK1	BRICK1, SCAR/WAVE actin-nucleating complex subunit	11.0	Publications
14	CIAPIN1	cytokine induced apoptosis inhibitor 1	11.0	Publications
15	CD24	CD24 molecule	11.0	Publications
16	PGPEP1	pyroglutamyl-peptidase I	11.0	Publications
17	RNPEP	arginyl aminopeptidase (aminopeptidase B)	11.0	Publications
18	BTG2	BTG family, member 2	11.0	Publications
19	T	T, brachyury homolog (mouse)	11.0	Publications
20	GREM1	gremlin 1	11.0	Publications
21	PSCA	prostate stem cell antigen	11.0	Publications
22	CD276	CD276 molecule	11.0	Publications
23	LRRC2	leucine rich repeat containing 2	11.0	Publications
24	NDRG2	NDRG family member 2	11.0	Publications
25	INHA	inhibin, alpha	11.0	Publications
26	ANGPTL4	angiopoietin-like 4	11.0	Publications
27	HTRA3	HtrA serine peptidase 3	11.0	Publications
28	HTRA2	HtrA serine peptidase 2	11.0	Publications
29	PGK1	phosphoglycerate kinase 1	11.0	Publications
30	CD70	CD70 molecule	11.0	Publications
31	CD74	CD74 molecule, major histocompatibility complex, class II invariant chain	11.0	Publications
32	FSCN1	fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus)	11.0	Publications
33	GRPR	gastrin-releasing peptide receptor	11.0	Publications
34	F11R	F11 receptor	11.0	Publications
35	RASSF1	Ras association (RalGDS/AF-6) domain family member 1	11.0	Publications
36	HAVCR1	hepatitis A virus cellular receptor 1	11.0	Publications
37	MOK	MOK protein kinase	11.0	Publications
38	FIGF	c-fos induced growth factor (vascular endothelial growth factor D)	11.0	Publications
39	PAX8	paired box 8	11.0	Publications
40	PAX2	paired box 2	11.0	Publications
41	RHOC	ras homolog family member C	11.0	Publications
42	SYT6	synaptotagmin VI	11.0	Publications
43	CA12	carbonic anhydrase XII	11.0	Publications
44	SFRP1	secreted frizzled-related protein 1	11.0	Publications
45	AQP1	aquaporin 1 (Colton blood group)	11.0	Publications
46	GTF3A	general transcription factor IIIA	11.0	Publications
47	RHOB	ras homolog family member B	11.0	Publications
48	SPINT2	serine peptidase inhibitor, Kunitz type, 2	11.0	Publications
49	CCNE1	cyclin E1	11.0	Publications
50	TGFBI	transforming growth factor, beta-induced, 68kDa	11.0	Publications

Pathways related to clear cell renal cell carcinoma according to GeneDecks:

(show top 50)    (show all 173)

id	Pathway	Score	Top Affiliating Genes
1	Transcription P53 signaling pathway10	10.5	VEGFA, CDK2, RELA
2	Renal cell carcinoma20	10.1	FIGF, RAF1, VHL, MET, ETS1, HIF1A
3	Breast Cancer Regulation by Stathmin136	9.6	FIGF, CCNE1, IGF1R, EGFR, TGFA, TIMP3
4	CREB Pathway36	9.5	KIT, TIMP3, IGF1R, FLT4, KDR, PRKCE
5	14-3-3 Induced Intracellular Signaling36	9.1	FIGF, VEGFC, RAF1, FLT4, FLT1, PRKCE
6	Akt Signaling36	9.0	TIMP3, PDGFRB, IGF1R, MDM2, MET, CXCR3
7	Focal adhesion20	8.9	EGFR, HGF, MET, RHOA, PDGFRB, SPP1
8	Rac1 Pathway36	8.9	FIGF, TIMP2, RAF1, KDR, FLT4, MET
9	JNK Pathway36	8.8	EPOR, DUSP9, TGFB1, PDGFRB, KIT, RAF1
10	Glioma20	8.8	CDKN1A, RAF1, CDK4, MDM2, MTOR, IGF1R
11	Melanoma20	8.7	CDKN1A, CDK4, CDH1, MET, MDM2, IGF1R
12	Glioblastoma Multiforme36	8.7	RAF1, CDK4, EGFR, E2F1, CDKN1A, CDK2
13	eIF2 Pathway36	8.7	EIF2AK3, EGFR, TIMP2, TGFA, HGF, VEGFC
14	Bladder cancer20	8.5	RAF1, RASSF1, CDKN1A, CDK4, CDH1, MMP2
15	PPAR Pathway36	8.5	KIT, VEGFC, RAF1, FLT1, FLT4, FIGF
16	eNOS Signaling36	8.4	EPOR, HGF, EGFR, PDGFRB, CAV1, CASP8
17	NF-KappaB (p50-p65) Pathway36	8.4	FIGF, KDR, RELA, VEGFC, FLT4, MET
18	PTEN Pathway36	8.4	TIMP3, PRKCE, HGF, KDR, FLT1, FLT4
19	Angiogenesis3	8.3	KDR, HIF1A, TYMP, TIMP2, TIMP3, TGFA
20	Ras Pathway36	8.3	IGF1R, MET, KDR, TGFA, TIMP3, TIMP2
21	NF-KappaB Family Pathway36	8.2	TLR3, HGF, TGFB1, FLT1, PRKCE, RELA
22	Prostate cancer20	8.2	MDM2, TCF7L2, E2F1, FOXO1, CDK2, CDKN1A
23	Small cell lung cancer20	8.1	FHIT, APAF1, PTEN, NFKB1, E2F1, CDK4
24	Chronic myeloid leukemia20	8.1	E2F1, RAF1, MYC, CDKN1A, CDKN1B, CDK4
25	P2Y Receptor Signaling36	8.1	KIT, KDR, PDGFRB, IGF1R, MET, FIGF
26	ILK Signaling36	8.0	KIT, MET, TNC, PTGS2, COL18A1, PDGFRB
27	ERK5 Signaling36	7.9	TIMP3, EGFR, PDGFRB, MET, FIGF, FLT4
28	DHA Signaling36	7.8	APAF1, IGF1R, CASP8, PDGFRB, EGFR, TIMP2
29	Apoptotic Pathways in Synovial Fibroblasts36	7.7	KIT, VEGFC, KDR, FLT1, FLT4, FIGF
30	Nanog in Mammalian ESC Pluripotency36	7.7	PDGFRB, IGF1R, MET, TIMP3, EGFR, TIMP2
31	Telomerase Components in Cell Signaling36	7.6	KIT, VEGFC, MYC, KDR, FLT1, FLT4
32	p53 Mediated Apoptosis36	7.5	KIT, VEGFC, KDR, FLT1, FLT4, FIGF
33	p70S6K Signaling36	7.5	F2R, FLT1, TGFB1, KDR, RAF1, VEGFC
34	GSK3 Signaling36	7.5	CDH1, KDR, VEGFC, FLT1, FLT4, FIGF
35	Mitochondrial Apoptosis36	7.4	KIT, VEGFC, TGFA, TGFB1, PRKCE, HGF
36	Cytokine-cytokine receptor interaction20	7.4	TGFB1, EPOR, KIT, VEGFA, VEGFC, KDR
37	Activation of PKC through GPCR36	7.3	FIGF, EGFR, TIMP3, HGF, PRKCE, TGFB1
38	GPCR Pathway36	7.3	FLT1, TGFA, TIMP3, TIMP2, IGF1R, MET
39	Estrogen Pathway36	7.2	TIMP3, KDR, KIT, HGF, TGFB1, TGFA
40	Cellular Apoptosis Pathway36	7.2	TIMP2, TIMP3, TGFA, TGFB1, PRKCE, HGF
41	ERK Signaling36	7.2	EPOR, TNC, PRKCE, TGFB1, TGFA, TIMP2
42	Phospholipase-C Pathway36	7.1	FLT4, FLT1, HGF, RAF1, FIGF, IGF1R
43	Activation of PKA through GPCR36	7.1	RAF1, VEGFC, KIT, EPOR, HGF, KDR
44	Rho Family GTPases36	7.0	TGFB1, TGFA, TIMP3, TIMP2, EGFR, PDGFRB
45	MAPK Signaling36	6.9	PRKCE, KDR, TIMP2, TCF7L2, TGFB1, MET
46	Renin-Angiotensin Pathway36	6.8	PTGS2, PDGFRB, EGFR, TIMP2, TIMP3, TGFA
47	JAK-STAT Pathway36	6.7	KDR, RAN, EPOR, EPO, TGFB1, MYC
48	Molecular Mechanisms of Cancer36	6.5	MET, TGFB1, TGFBR2, PRKCE, E2F1, HGF
49	Pathways in cancer20	6.1	E2F1, SLC2A1, TCF7L2, TGFBR2, TGFB1, TGFA
50	Pancreatic Adenocarcinoma36	5.4	CDKN1A, CDK2, CDKN1B, CDK4, MMP2, MMP9

Compounds related to clear cell renal cell carcinoma according to GeneDecks:

(show top 50)    (show all 315)

id	Compound	Score	Top Affiliating Genes
1	glucose32	9.7	KIT, SETD2, SERPINF1, VHL, VEGFC, CGB
2	threonine32	9.6	RAF1, PAX8, PAX2, CDKN1B, ANPEP, F2R
3	arginine32	9.2	RAN, CDK2, CDK4, MME, MDM2, IFI27
4	hyaluronic acid32 18	10.0	VIM, MYC, MUC1, CDH1, IGF1R, CALB2
5	lovastatin32 42 9 9	11.8	SERPINE1, RAF1, CDKN1A, CDK2, CDKN1B, CDK4
6	estradiol32 9 18 9	11.7	SERPINE1, VIM, VEGFC, BIRC5, MUC1, MTOR
7	pge232	8.6	SETD2, RAF1, CDH1, MME, IGF1R, LOX
8	sunitinib32 9 9	10.6	KIT, VHL, VEGFA, RAF1, KDR, MTOR
9	ascorbic acid32 18	9.6	SETD2, RAF1, CDK4, MME, MMP2, IGF1R
10	geldanamycin32 9 9	10.4	SETD2, VEGFA, RAF1, BIRC5, KDR, CDKN1A
11	lactacystin32	8.3	MYC, RAF1, BIRC5, CDKN1A, CDK2, CDKN1B
12	tacrolimus32 34 9 9	11.0	SERPINE1, MYC, RAF1, MTOR, CDK4, IGF1R
13	agar32	8.0	VIM, RASSF1, BIRC5, MUC1, CDK2, CDKN1B
14	sb 20358032 42	9.0	SETD2, VIM, VEGFA, BIRC5, CDKN1A, CDKN1B
15	glycogen32 18	9.0	KIT, SFRP1, SETD2, VIM, VHL, MYC
16	silymarin32	7.9	VEGFA, BIRC5, CDK2, CDK4, MMP2, MMP9
17	nitric oxide32 9 18 9	10.7	KIT, SERPINF1, VHL, VEGFC, BIRC5, KDR
18	glutamate32	7.7	SERPINF1, VIM, KDR, CDK2, CDKN1B, CDH1
19	tgf beta132	7.6	SETD2, SERPINE1, KDR, CDKN1A, CDK2, CDKN1B
20	calcitriol32 42 9 18 9	11.6	MYC, CDKN1A, CDK2, CDKN1B, CDK4, CDH1
21	gemcitabine32 34 9 9	10.6	VEGFA, MYC, BIRC5, KDR, MUC1, CDKN1A
22	ag 147832	7.5	SERPINE1, RAF1, CDK2, CDKN1B, MMP2, MMP9
23	lipid32	7.5	SETD2, SERPINE1, VIM, VEGFC, BIRC5, MUC1
24	cysteine32	7.5	SERPINF1, RAF1, RAN, PARK7, KDR, MUC1
25	5-aza-2deoxycytidine32	7.4	SFRP1, SEMA3B, VIM, VHL, MYC, RASSF1
26	oxygen32 18	8.3	SETD2, SERPINF1, RAN, BIRC5, PARK7, CDKN1A
27	wortmannin32 42	8.1	SETD2, VIM, RAF1, BIRC5, KDR, MTOR
28	celecoxib32 42 34 9 18 9	12.0	VEGFA, BIRC5, KDR, CDKN1A, CDK2, CDKN1B
29	tamoxifen32 34 9 9	9.8	VIM, VEGFA, MYC, RAF1, BIRC5, KDR
30	ribonucleic acid32	6.7	KIT, VEGFC, MYC, PAX8, MUC1, MME
31	cyclosporin a32 42	7.6	MYC, RAF1, KDR, MTOR, CDK2, CDK4
32	matrigel32	6.6	SERPINF1, SERPINE1, VIM, VEGFA, VEGFC, KDR
33	estrogen32	6.5	BTG2, SETD2, SERPINE1, VHL, VEGFC, RAF1
34	calcium32 9 18 9	9.5	RELA, KIT, SERPINF1, VHL, VEGFC, BIRC5
35	5fluorouracil32	6.5	KIT, VEGFA, BIRC5, KDR, MUC1, MTOR
36	doxorubicin32 34 9 9	9.4	KIT, SETD2, VIM, RAF1, KDR, MTOR
37	methotrexate32 34 42 9 9	10.3	KIT, SERPINE1, VIM, BIRC5, MUC1, CGB
38	lactate32	6.3	KIT, SETD2, VIM, BIRC5, KDR, CGB
39	curcumin32	6.2	VEGFA, MYC, RAF1, BIRC5, CDKN1A, CDK2
40	butyrate32	6.1	SETD2, VIM, MYC, RAF1, BIRC5, MUC1
41	alanine32	5.7	VIM, MYC, RAF1, RAN, RASSF1, BIRC5
42	retinoic acid32 42 18	7.4	KIT, SETD2, SEMA3B, SERPINF1, SERPINE1, VEGFC
43	actinomycin d32	5.4	KIT, SETD2, SERPINE1, VIM, VHL, VEGFA
44	thymidine32 18	6.3	KIT, VEGFC, MYC, RAF1, BIRC5, KDR
45	dexamethasone32 42 34 9 9	9.1	SERPINF1, SERPINE1, VIM, VEGFA, VEGFC, MYC
46	genistein32 9 18 9	7.8	SETD2, SERPINE1, VIM, VEGFA, MYC, RAF1
47	pd 98,05932	4.4	KIT, SETD2, SERPINE1, VEGFC, MYC, RAF1
48	paclitaxel32 34 9 9	7.4	KIT, SETD2, VIM, VEGFA, MYC, RAF1
49	paraffin32	3.9	RELA, KIT, VIM, VEGFA, VEGFC, MYC
50	cisplatin32 34 9 9	6.5	SETD2, VEGFA, MYC, RAF1, RAN, RASSF1

Cellular components related to clear cell renal cell carcinoma according to GeneDecks:

(show all 13)

id	Name	GO ID	Score	Top Affiliating Genes
1	cyclin-dependent protein kinase holoenzyme complex	GO:000307	10.1	CDK4, CCNE1, CDKN1A, CDK2
2	extracellular matrix	GO:031012	9.7	COL18A1, TNC, SERPINE1, SERPINF1, TIMP3, TGFBI
3	external side of plasma membrane	GO:009897	9.7	CXCR3, TGFBR2, ANPEP, ENPEP, CD74, CD276
4	platelet alpha granule lumen	GO:031093	9.2	TGFB1, FIGF, VEGFC, VEGFA, SERPINE1, HGF
5	cell surface	GO:009986	9.0	CDH1, TGFB1, DPP4, ROBO1, EPCAM, TGFA
6	integral to plasma membrane	GO:005887	8.7	FLT1, MME, CD70, MUC1, KDR, FLT4
7	nucleoplasm	GO:005654	8.3	CDK4, PAX8, RAN, MYC, VHL, RELA
8	cytosol	GO:005829	6.8	FOXO1, FHIT, APAF1, FADD, ANPEP, CCNE1
9	extracellular space	GO:005615	6.8	FLT1, MMP9, MMP2, VEGFC, VEGFA, SERPINE1
10	extracellular region	GO:005576	INF	MMP2, MMP9, FLT4, FIGF, INHA, ANGPTL4
11	cytoplasm	GO:005737	INF	ROBO1, NFKB1, SPINT2, DACH1, PTGS2, PTEN
12	plasma membrane	GO:005886	INF	GNAS, F11R, CA9, EPCAM, ROBO1, GRPR
13	nucleus	GO:005634	INF	GTF3A, RELA, FLT1, , FLT4, FHIT

Biological processes related to clear cell renal cell carcinoma according to GeneDecks:

(show top 50)    (show all 72)

id	Name	GO ID	Score	Top Affiliating Genes
1	cellular response to hydrogen peroxide	GO:070301	10.7	PARK7, AQP1, ETS1, RHOB, PAX2
2	metanephric distal convoluted tubule development	GO:072221	10.5	PAX8, PAX2, CALB1
3	response to mechanical stimulus	GO:009612	10.4	MMP9, CAV1, ETS1, TIMP3, RHOC, BTG2
4	cellular response to vascular endothelial growth factor stimulus	GO:035924	10.3	MT1G, KDR, VEGFA, FLT1, FLT4
5	vasculogenesis	GO:001570	10.3	T, CAV1, WT1, TGFBR2, VEGFA, KDR
6	induction of apoptosis by intracellular signals	GO:008629	10.3	CASP8, MYC, CDKN1A, CD24, APAF1, HTRA2
7	cellular response to stress	GO:033554	10.2	VHL, VEGFA, EPAS1, EPO, AQP1, HIF1A
8	regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:061418	10.2	EPAS1, HIF1A, CA9, VEGFA, VHL, EPO
9	vascular endothelial growth factor receptor signaling pathway	GO:048010	10.1	FLT4, FIGF, PDGFRB, VEGFA, VEGFC, KDR
10	proteolysis	GO:006508	10.1	DPP4, CASP8, HTRA3, HTRA2, NPEPPS, VHL
11	positive regulation of vasoconstriction	GO:045907	10.0	F2R, ALOX5, CAV1, RHOC, PTGS2
12	cellular response to interleukin-1	GO:071347	10.0	MMP9, NFKB1, HIF1A, SFRP1, RELA
13	positive regulation of fibroblast proliferation	GO:048146	10.0	EGFR, E2F1, AQP1, CDK4, CD74, CDKN1A
14	connective tissue replacement involved in inflammatory response wound healing	GO:002248	9.9	TGFB1, HIF1A, F2R
15	positive regulation of angiogenesis	GO:045766	9.8	MMP9, FLT1, GREM1, AQP1, HIF1A, RHOB
16	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	GO:043154	9.8	BIRC5, RAF1, VEGFA, PAX2, HGF, AQP1
17	phosphatidylinositol-mediated signaling	GO:048015	9.7	CDKN1B, RHOA, PDGFRB, PTEN, IGF1R, MDM2
18	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	9.7	HGF, KIT, KDR, FLT1, PDGFRB, F2R
19	cell migration involved in sprouting angiogenesis	GO:002042	9.6	ROBO1, VEGFA, KDR, GREM1
20	positive regulation of MAPK cascade	GO:043410	9.6	KDR, PRKCE, F2R, KIT, FLT4, FLT1
21	organ regeneration	GO:031100	9.6	CDKN1A, PPARG, HGF, TGFB1, CCNE1, MKI67
22	response to estrogen stimulus	GO:043627	9.5	SERPINE1, CD24, PPARG, TIMP3, EPO, CAV1
23	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	9.5	CDKN1B, ROBO1, APAF1, FADD, IFI27, F2R
24	response to hyperoxia	GO:055093	9.5	SERPINE1, EPO, MMP9, ALOX5, CDKN1A
25	cell proliferation	GO:008283	9.4	ENPEP, GRPR, E2F1, TCF7L2, TGFBI, TGFA
26	positive regulation of epithelial cell proliferation	GO:050679	9.3	TGFB1, TGFA, EGFR, PAX2, MYC, VEGFC
27	angiogenesis	GO:001525	9.3	KDR, MMP2, FIGF, ENPEP, ANPEP, ANGPTL4
28	virus-host interaction	GO:019048	9.3	TGFB1, HAVCR1, MDM2, FADD, KDR, KRT7
29	positive regulation of MAP kinase activity	GO:043406	9.3	PDGFRB, CD24, FLT1, VEGFA, EGFR, TGFB1
30	induction of apoptosis	GO:006917	9.3	PRKCE, INHA, TGFB1, PTEN, CD70, WT1
31	anti-apoptosis	GO:006916	9.2	RELA, TERT, ETS1, IGF1R, FOXO1, CIAPIN1
32	cellular response to hypoxia	GO:071456	9.2	VHL, SFRP1, EPO, EPAS1, E2F1, NPEPPS
33	response to hypoxia	GO:001666	9.1	ETS1, MMP9, FLT1, FIGF, ANGPTL4, TGFB1
34	cell cycle arrest	GO:007050	9.1	MYC, HTRA2, TGFB1, INHA, CDKN1B, CDKN1A
35	positive regulation of cell migration	GO:030335	9.1	TGFB1, VEGFA, KDR, FLT1, IGF1R, ETS1
36	MAPK cascade	GO:000165	9.0	TGFB1, RAF1, CAV1, DOK4, EGFR, TGFA
37	nerve growth factor receptor signaling pathway	GO:048011	9.0	RELA, MDM2, PRKCE, CDKN1B, FOXO1, MTOR
38	protein autophosphorylation	GO:046777	9.0	PDGFRB, MTOR, KDR, FLT4, MET, IGF1R
39	platelet activation	GO:030168	9.0	TGFB1, RHOB, RHOA, SERPINE1, FIGF, RAF1
40	negative regulation of transcription, DNA-dependent	GO:045892	8.9	FOXO1, BIRC5, GREM1, RELA, PPARG, SFRP1
41	apoptotic process	GO:006915	8.8	NFKB1, RHOB, TGFBR2, CXCR3, E2F1, DIABLO
42	blood coagulation	GO:007596	8.7	TGFB1, RHOA, PRKCE, CAV1, F11R, SERPINE1
43	positive regulation of transcription from RNA polymerase II promoter	GO:045944	8.6	VEGFA, FOXO1, GREM1, FADD, RELA, PAX8
44	positive regulation of transcription, DNA-dependent	GO:045893	8.5	FOXO1, WT1, NFKB1, CCNE1, F2R, ETS1
45	negative regulation of cell proliferation	GO:008285	8.5	PTGS2, RNF139, TIMP2, TGFB1, TFAP2A, COL18A1
46	epidermal growth factor receptor signaling pathway	GO:007173	8.3	MDM2, EGFR, TGFB1, FOXO1, CDKN1B, MTOR
47	response to drug	GO:042493	8.1	SFRP1, VEGFC, MYC, PARK7, PTGS2, TGFBR2
48	signal transduction	GO:007165	8.0	RAF1, ANGPTL4, IGF1R, TNC, PPARG, EGFR
49	negative regulation of apoptotic process	GO:043066	7.8	ANGPTL4, MDM2, AQP1, FLT4, CD74, CDKN1B
50	positive regulation of cell proliferation	GO:008284	6.6	KDR, T, CDK2, CDKN1B, CDK4, FLT1

Molecular functions related to clear cell renal cell carcinoma according to GeneDecks:

(show all 13)

id	Name	GO ID	Score	Top Affiliating Genes
1	aminopeptidase activity	GO:004177	10.6	NPEPPS, DNPEP, ENPEP, DPP4, RNPEP, ANPEP
2	platelet-derived growth factor receptor binding	GO:005161	10.3	PDGFRB, VEGFA, FIGF, TYMP
3	insulin-like growth factor binding	GO:005520	10.2	IGF1R, ESM1, HTRA3, IGFBP3
4	vascular endothelial growth factor-activated receptor activity	GO:005021	10.1	KDR, FLT1, FLT4, PDGFRB
5	receptor binding	GO:005102	9.9	SERPINE1, INHA, DPP4, PDGFRB, ANGPTL4, CD70
6	transcription regulatory region DNA binding	GO:044212	9.9	HIF1A, TCF7L2, WT1, NFKB1, PAX2, PAX8
7	growth factor activity	GO:008083	9.6	TGFB1, HGF, TYMP, TGFA, ESM1, VEGFC
8	protein phosphatase binding	GO:019903	9.2	CDH1, EGFR, EIF2AK3, FLT4, CDKN1B
9	transmembrane receptor protein tyrosine kinase activity	GO:004714	9.2	KIT, KDR, FLT1, FLT4, EGFR
10	protein heterodimerization activity	GO:046982	8.6	EPAS1, VEGFA, MYC, BIRC5, SYT6, TGFB1
11	identical protein binding	GO:042802	8.4	VIM, RAF1, RASSF1, BIRC5, CD74, FLT1
12	enzyme binding	GO:019899	8.0	SLPI, VHL, MDM2, CAV1, PTEN, PTGS2
13	protein binding	GO:005515	INF	MMP9, IGF2BP3, IGFBP3, LOX, HTRA2, HTRA3